Arbutus Biopharma


Arbutus Biopharma Corporation (NASDAQ:ABUS) is a publicly-traded biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by hepatitis B virus (HBV).

Industries

Employees

51-200

Links


Org chart

Collapse
Elizabeth Howard
EVP, General Counsel & Chief Compliance Officer
Michael J. Sofia Phd
Chief Scientific Officer
Matt Addiego
Executive Director Of Information Technology & Information Security
Tuan Nguyen
Chief Financial Officer
Tilly Varughese
Medical Director

Board & advisors

Frank Torti
Chairman
Daniel Burgess
Independent Director
Richard C. Henriques
Independent Director
Keith Manchester
Independent Director